Advancing Small-Molecule Discovery with AI: Boltz Gains Momentum AI-native drug discovery company Boltz has announced a $28 million seed financing alongside a strategic collaboration with Pfizer, marking a significant step forward in the application of artificial intelligence to small-molecule drug discovery. The newly raised capital will support the expansion of Boltz’s platform, which is designed…
Breakthrough in Small-Molecule Discovery Targets “Undruggable” Cancers A research team at UCLA Health Jonsson Comprehensive Cancer Center has identified a novel small molecule that could unlock an entirely new class of cancer treatments—particularly for malignancies long considered difficult or impossible to treat. The newly discovered compound targets IGF2BP3, an RNA-binding protein that plays a key…
Small-Molecule Drug Discovery in 2025 Where the Market Stands—and How Far It Could Grow by 2030–2035 Small molecules—typically orally available, chemically synthesized drugs—remain the workhorse modality of modern therapeutics. In 2025, they continue to anchor pipelines across oncology, immunology, cardiovascular disease, and CNS, thanks to their ability to reach intracellular targets, scale reliably, and follow…
AI-Driven Molecular Representation Advances Scaffold Hopping A New Era for Small-Molecule Drug Discovery Small-molecule therapeutics remain foundational to modern medicine, supporting treatment across oncology, immunology, cardiovascular disease, and CNS disorders. Yet identifying new molecules with the right balance of potency, selectivity, and pharmacokinetic properties remains one of the most persistent challenges in drug discovery. One…
New Biocompatible Frameworks: Small-Molecule HOFs Open the Door to Advanced Bio-Applications In a notable advance that bridges chemistry, materials science, and biotechnology, researchers have developed a new class of highly ordered, macroporous frameworks constructed from small, biocompatible molecules. These frameworks — a type of Hydrogen‑bonded Organic Frameworks (HOFs) — combine structural robustness, large pore sizes,…
Clusterin Enhancer Alzheimer’s Therapy: A Small-Molecule Approach Researchers have identified a clusterin enhancer Alzheimer’s therapy based on a small-molecule drug candidate that boosts levels of a naturally protective brain protein and restores memory in Alzheimer’s disease (AD) mouse models. This discovery offers a promising alternative to traditional amyloid- or tau-centric treatment strategies. Why Clusterin…
IGF2BP3 Inhibitor I3IN-002 Shows Promise Against Hard-to-Treat Leukaemia Researchers have identified a small-molecule inhibitor of the RNA-binding protein IGF2BP3 that demonstrates potent anti-leukaemic activity in both cellular and animal models. The compound, I3IN-002, disrupts IGF2BP3–RNA interactions, suppresses leukaemia cell proliferation, and induces apoptosis — representing a major advance in targeting RNA-binding proteins long considered “undruggable.”…